Century Therapeutics, Inc. Common Stock (IPSC) is a publicly traded Healthcare sector company. As of May 21, 2026, IPSC trades at $2.25 with a market cap of $411.21M and a P/E ratio of -15.75. IPSC moved +6.37% today. Year to date, IPSC is +126.27%; over the trailing twelve months it is +275.00%. Its 52-week range spans $0.34 to $3.04. Analyst consensus is strong buy with an average price target of $5.20. Rallies surfaces IPSC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Century Therapeutics Eyes IND Filing for Diabetes Therapy, Holds $217M Runway: Century Therapeutics advanced its CNTY-813 type 1 diabetes iPSC-derived islet therapy through IND-enabling studies, aiming to file an IND in Q4 2026 with initial clinical data in H2 2027. Cash, cash equivalents and marketable securities totaled $217M on March 31, 2026, providing runway into Q1 2029.
| Metric | Value |
|---|---|
| Price | $2.25 |
| Market Cap | $411.21M |
| P/E Ratio | -15.75 |
| EPS | $-0.14 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.04 |
| 52-Week Low | $0.34 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $109.16M |
| Net Income | $-9.58M |
| Gross Margin | 0.00% |
4 analysts cover IPSC: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.20.